Articles tagged with Blood Diseases
The Helmholtz Munich researchers developed a neural network that outperforms previous machine learning algorithms for cell classification in terms of accuracy and generalizability. The database consists of over 170,000 single-cell images from more than 900 patients with various blood diseases.
A recent study published in JNCCN found that only 31% of hospitals have immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. This medication is essential for treating acute promyelocytic leukemia, which has a better prognosis when treated appropriately. The lack of ATRA availability poses a signi...
People with blood cancers are at higher risk of severe COVID-19 illness; research suggests they don't always achieve optimal protection from vaccination. A new study found that patients with lymphoma were more likely to develop post-vaccination COVID-19 infection compared to those with other blood cancers.
A study suggests that suppressing the protective mechanisms of rogue blood stem cells can help curb clonal hematopoiesis and prevent leukemia. The researchers used zebrafish with colored 'barcodes' to track the dominance of cancerous clones, revealing a connection between anti-inflammatory genes and resistance to inflammation.
A team of Lehigh University undergraduates has won the National Institutes of Health's Healthcare Technologies for Low-Resource Settings Prize for developing a diagnostic device to detect sickle cell disease in infants. The $15,000 prize will support further development and testing of the device, which could improve healthcare outcomes...
Ulrich Steidl, a leading cancer researcher, has received an NCI grant to study the molecular mechanisms of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The goal is to develop new treatments and cures for these fatal disorders.
Researchers have discovered that red blood cells bind to cell-free DNA during sepsis and COVID-19, leading to their removal from circulation and triggering inflammation. This finding opens the door to new treatments for inflammatory diseases and acute anemia.
Researchers at the University at Buffalo have developed a new treatment that pairs essential proteins with lysophosphatidylserine to build immune tolerance and prevent antibody development, potentially treating autoimmune disorders and allergies.
A new precision medicine test has been developed using blood proteins to identify patients with idiopathic multicentric Castleman disease (iMCD) most likely to respond to siltuximab. The study also reveals Janus kinase (JAK) inhibitors as a promising alternative treatment option for those who do not respond to siltuximab.
A validated definition for iMCD-TAFRO has been established to differentiate it from other iMCD cases, enabling timely diagnosis and proper treatment. The new definition includes four clinical criteria: thrombocytopenia, anasarca, fever, and organomegaly.
Scientists at University of California San Diego School of Medicine have developed a method to keep cultured hematopoietic stem cells healthy, positive news for patients seeking stem cell transplants. The findings also hint at a new way to ward off aging by super-activating the heat shock pathway.
Researchers at Ural Federal University create enzyme-free electrocatalytic sensors using palladium and silver, increasing sensitivity and accuracy. The new method reduces storage needs and costs, making glucose measurement more reliable and accessible.
Researchers discovered epigenetic variations in individuals with severe COVID-19, associating them with excessive inflammatory response and poor health state. These findings enable the identification of a high-risk group (EPICOVID), warranting special care and personalized medicine approaches.
A multiyear workplace health promotion program was shown to prevent health risks among working-age individuals. The study found that participants remained at the same level or improved their rating, while only a small percentage deteriorated.
Researchers analyzed data from over 3.6 million women to identify differences in hypertensive disorders of pregnancy among US states. The study found significant variations in prevalence rates, suggesting regional disparities in maternal health care.
Research from Edith Cowan University found that consuming higher amounts of cruciferous vegetables daily can lower the risk of extensive calcification on the aorta, a key marker for structural blood vessel disease. Vitamin K may play a role in inhibiting this calcification process.
Researchers are studying gene transcription in blood of patients undergoing buprenorphine treatment to understand its therapeutic effects. The study aims to identify key genes and their association with clinical results, potentially leading to new treatments for opioid use disorder.
A study of nearly 1,000 mother-child pairs found an association between fetal exposure to acetaminophen and increased risk of childhood attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The research used umbilical cord blood samples to investigate potential developmental effects.
Researchers found elevated first trimester blood pressure increases risk for pregnancy hypertensive disorders, such as gestational high blood pressure and preeclampsia. Women with higher systolic or diastolic pressures had a greater risk of developing these conditions.
Stem cells derived from fat tissue can now be used to produce functioning platelets in just 12 days. This breakthrough could provide a reliable and safe supply of platelets for patients with cancer and other disorders, reducing the reliance on donated platelets.
Research found that individuals with diabetes who switched to high-deductible health plans experienced delays in seeking care for symptoms of blood vessel diseases, including cardiac chest pain and transient ischemic attacks. The study suggests that increased out-of-pocket costs lead to changes in healthcare behavior.
Researchers identified three key proteins that determine blood vessel growth and behavior, which may become new therapeutic targets. A novel approach focusing on endothelial cell metabolism could outperform current anti-VEGF therapies in efficacy.
The study estimated high mortality rates among civilians in Mosul, Iraq, with a rate of 2.09 deaths per 1,000 person-months during the 9 months of military liberation, compared to 0.71 and 0.50 deaths per 1,000 person-months during ISIS control periods for males and females, respectively.
A new study from The George Institute for Global Health at the University of Oxford found a strong link between high blood pressure and mitral regurgitation, a condition that makes the heart less efficient at pumping blood. Lowering blood pressure through exercise, diet or medication may reduce the risk of developing this condition.
A new study found that women with preeclampsia are seven times more likely to have severe preeclampsia or eclampsia if they also have pregnancy-associated stroke. Infections and chronic high blood pressure were also linked to an increased risk of stroke in these women.
The Endocrine Society has issued a statement advising healthcare providers on how to spot hormonal causes of high blood pressure that can be cured with surgery or treated effectively with medication. Screening for underlying conditions is crucial to prevent cardiovascular disease, renal disease, and even death.
A new color-coding tool enables scientists to track live blood stem cells over time, revealing how blood disorders and cancers like leukemia arise. The tool has many implications for hematology and cancer medicine, including understanding clonal diversity and regulating its development.
A single mutated gene, SNORD118, has been found to cause leukoencephalopathy with calcification and cysts (LCC), a progressive white matter degeneration in the brain. This discovery opens up possibilities for genetic testing and future treatments.
A Phase III trial shows the engineered clotting protein rvWF is safe and effective in controlling bleeding episodes in patients with severe vW disease. The protein increases naturally produced FVIII levels, reducing the need for additional infusions.
A study published in The Journal of Cell Biology provides new insights into the relationship between two proteins associated with cerebral cavernous malformations. Researchers found that CCM3 has an independent role in cell proliferation or survival pathways, contributing to the severity of symptoms.
AP39 replenishes hydrogen sulfide levels, lowering heart rate and blood pressure, with potential for new cardiovascular therapies.
A pilot study found using a smartphone app for education and feedback about heart-healthy behavior decreased the risk of heart disease in young black women. The treatment group showed improved blood pressure, cholesterol levels, stress, anxiety, and healthy habits compared to the control group.
A new theory proposes that preeclampsia is caused by the body's response to insufficient oxygen and nutrient supply to the growing fetus, leading to high blood pressure and organ damage. The condition can have fatal complications for pregnant women and their babies if left untreated.
Researchers developed synthetic platelet-like particles that can augment natural blood clotting, potentially reducing trauma-related bleeding deaths. The particles were tested in animal models and human blood, showing effectiveness in slowing bleeding without causing adverse effects.
Rice University researchers have discovered a biochemical link between blood clotting and the immune system, which could lead to new treatments for patients with inflammatory diseases. The study found that a protein involved in blood clotting also triggers the body's immune response.
Researchers propose a novel risk stratification model for bladder cancer patients treated with radical cystectomy, utilizing clinico-pathological and pre-operative hematological factors. The study found that low hemoglobin and high C-reacted protein levels are independent prognostic indicators for disease-specific survival.
Researchers examined current treatment standards for patients with clotting disorders, aiming to reduce toxicities and relapse rates. Maintaining hematocrit levels below 45% was associated with a lower risk of thrombosis compared to a more liberal approach.
Researchers at UW-Madison have identified a small DNA sequence, the +9.5 GATA2 switch site, that plays a crucial role in controlling GATA2 production and generating self-renewing blood stem cells.
A Finnish research team has uncovered the protein structure that regulates cell signalling and blood cell formation, shedding light on haematological disorders. The study provides new opportunities for disease-specific treatment and may lead to targeted therapeutics for common myeloproliferative diseases.
Researchers discovered that 40% of LGL patients have a STAT3 mutation, which may aid in diagnosing and treating the disease. The mutation is also associated with an increased risk of rheumatoid arthritis, opening new avenues for understanding its pathogenesis.
A small study of 25 patients with hereditary hemorrhagic telangiectasia found improved cardiac output and reduced duration and number of episodes of nose bleeds after receiving bevacizumab. The treatment also significantly improved quality of life, with moderate toxicity observed.
The National Institutes of Health has signed a research and development agreement with two non-profit organizations to develop potential clinical therapies for rare blood cancers. The collaboration aims to bridge the gap between basic research and human testing, with the goal of accelerating the delivery of improved therapies to patients.
Researchers found that N-acetylcysteine reduces the size and activity of von Willebrand factor multimers in human plasma and mice, offering a potential rapid treatment for patients with TTP. The study suggests that this approach could be effective in reducing complications associated with current treatments.
A study has revealed a relationship between blood cells and their stem cell 'parents', influencing gene expression and behavior. The discovery opens up new research avenues into diseases caused by stem cell disorders.
Researchers from Massachusetts General Hospital are leading teams to develop stem-cell-based models of cardiovascular and blood disorders. The NHLBI grants will support the development of regenerative therapies for heart failure and other disorders.
Researchers analyzed 17,398 patient records and found only 14 real disease associations with MGUS, not 61 as previously reported. This finding may reduce unnecessary testing and treatment for patients with MGUS.
A study found that miR-143 and miR-145 regulate the contractile nature of vascular smooth muscle cells, with their absence leading to increased tissue matrix production and signs of blood vessel disease. The findings suggest these microRNAs could serve as therapeutic targets for enhancing blood vessel repair.
Researchers identified a common genetic sequence alteration that enhances the likelihood of acquiring a mutation in a gene linked to certain blood diseases. Patients with myeloproliferative neoplasms have a higher risk of developing another JAK2 mutation due to inherited DNA sequence changes.
Researchers at Yale School of Medicine developed a man-made anti-clotting protein that prevents excessive clotting in patients with hereditary antithrombin deficiency. The treatment showed no adverse effects during treatment or seven days after treatment, indicating its potential to prevent complications linked to the condition.
The American Society of Hematology has launched an initiative to provide increased support for training programs in hematology-related disciplines. Three grant recipients will develop new curricula that integrate emerging technologies into traditional training programs, addressing the need for clinicians and clinical researchers with s...
International health experts call for urgent action from international development banks and pharmaceutical companies to address blood pressure-related diseases affecting developing countries. The authors argue that deaths from heart disease and stroke are largely avoidable but lack of effort has resulted in over 50 million deaths, wit...
The NHLBI-funded program aims to translate knowledge into clinical practice for treating heart, lung, and blood diseases. It focuses on repairing damaged heart muscle, reducing immune complications, and enhancing adult stem cell interactions.
Researchers have identified the Dido gene as a potential tumor suppressor involved in myeloproliferative diseases. The study found that 100% of patients with these diseases had Dido expression abnormalities, suggesting a link between the gene and the development of MDS/MPD.
A new diagnostic test is being developed to target a range of blood disorders by detecting a single point mutation in the JAK2 gene. The mutation was found in virtually all patients with polycythaemia vera, as well as half of those with essential thrombocythaemia and idiopathic myelofibrosis.
A French study found that intravenous immunoglobulin improved platelet counts in adults with AITP. The study also showed that oral steroids and placebo had similar efficacy rates. The researchers suggest judicious observation for patients without severe bleeding and recommend specific immune-based therapies.
Researchers found that half of patients admitted to hospital with life-threatening symptoms of heart failure had diastolic heart failure, a previously under-studied disorder. The study emphasizes the need for further research into treatment options for this common form of heart failure.
A Phase III study found significant improvements in overall survival, disease-free status, and complete remission rates for patients with aggressive non-Hodgkin's lymphoma treated with MabThera and CHOP chemotherapy. Survival at 1-year was 83% for the rituximab combination therapy group compared to 68% for those receiving CHOP alone.
Mayo Clinic researchers have developed a new antibody test to help diagnose autonomic disorders caused by the immune system. The test detects antibodies that bind to an important protein on autonomic nerve cells, helping physicians evaluate patients with autonomic failure.
A nationwide consortium of nine institutions aims to improve treatment outcomes for children with neuroblastoma by testing new therapies and sharing research information. The project has already shown promising results in improving disease-free survival rates and may lead to faster development of effective treatments.
A new study shows Bexxar produced tumor shrinkage in 97% of patients with advanced-stage, low-grade non-Hodgkins lymphoma. Most patients achieved complete remission, with no sign of cancer, and molecular remissions lasting up to three years.